Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 9Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Carcinoma, Medullary 3Carcinoid Tumor 3Adrenocortical Carcinoma 3Adenocarcinoma, Follicular 3Pheochromocytoma 2Paraganglioma 2Carcinoma, Renal Cell 2Carcinoma, Neuroendocrine 2Adenoma, Islet Cell 2Wilms Tumor 1Thyroid cancer, medullary 1Thyroid cancer, follicular 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Paraganglioma, Extra-Adrenal 1Osteosarcoma 1Non functioning pancreatic endocrine tumor 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1High Grade Neuroendocrine Neoplasms 1Hepatoblastoma 1

Interventions

veliparib 1cabozantinib 1X-Rays 1Temozolomide 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non functioning pancreatic endocrine tumor × cabozantinib × Endocrine × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡